Cargando…
Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis
Atherosclerosis (AS) and cancers are major global causes of mortality and morbidity. They also share common modifiable pathogenesis risk factors. As the same strategies used to predict AS could also detect certain cancers, we sought novel serum antibody biomarkers of cancers in atherosclerotic sera...
Autores principales: | Hu, Liubing, Liu, Jiyue, Shimada, Hideaki, Ito, Masaaki, Sugimoto, Kazuo, Hiwasa, Takaki, Zhou, Qinghua, Li, Jianshuang, Shen, Si, Wang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152111/ https://www.ncbi.nlm.nih.gov/pubmed/35656505 http://dx.doi.org/10.3389/fonc.2022.870086 |
Ejemplares similares
-
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer
por: Ito, Masaaki, et al.
Publicado: (2021) -
Cherub versus brat
por: Malin, Jennifer A, et al.
Publicado: (2018) -
Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker
por: Nanami, Tatsuki, et al.
Publicado: (2021) -
The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
por: Ito, Masaaki, et al.
Publicado: (2023) -
BraTS Toolkit: Translating BraTS Brain Tumor Segmentation Algorithms Into Clinical and Scientific Practice
por: Kofler, Florian, et al.
Publicado: (2020)